Authors
Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson Wurapa, Moti Ramgopal, Dushyantha T Jayaweera, Peter A Leone, Jessica E Matthews, Michael Cupo, Mark R Underwood, Konstantinos Angelis, Brian R Wynne, Deanna Merrill, Christopher Nguyen, Jean van Wyk, Andrew R Zolopa
Publication date
2023/3/1
Journal
Open forum infectious diseases
Volume
10
Issue
3
Pages
ofad101
Publisher
Oxford University Press
Description
Background
We assessed the efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in a US test-and-treat setting at a secondary 48-week time point of the multicenter, single-arm, phase IIIb STAT study.
Methods
Participants were eligible adults newly diagnosed with human immunodeficiency virus (HIV)-1 and had started once-daily DTG/3TC within 14 days of diagnosis, before laboratory results were available. Antiretroviral therapy (ART) was modified if baseline testing indicated DTG or 3TC resistance, hepatitis B virus (HBV) coinfection, or creatinine clearance <30 mL/min per 1.73 m2, and these participants remained in the study. A proportion with HIV-1 ribonucleic acid (RNA) <50 copies/mL at Week 48 was calculated among all participants (intention-to-treat-exposed [ITT-E] missing = failure analysis) and those with available data (observed analysis …
Total citations
Scholar articles
CP Rolle, M Berhe, T Singh, R Ortiz, A Wurapa… - Open forum infectious diseases, 2023